• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Solventum Corporation

    8/18/25 5:03:26 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care
    Get the next $SOLV alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Solventum Corporation

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    83444M101

    (CUSIP Number)


    08/15/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    83444M101


    1Names of Reporting Persons

    3M Company
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    25,569,190.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    25,569,190.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    25,569,190.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    14.8 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Solventum Corporation
    (b)Address of issuer's principal executive offices:

    3M Center, Building 275-6W, 2510 Conway Avenue East, Maplewood, MN, 55114
    Item 2. 
    (a)Name of person filing:

    3M Company
    (b)Address or principal business office or, if none, residence:

    3M Center, St. Paul, MN 55144-1000
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    83444M101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    25,569,190 shares of common stock. As of August 15, 2025, 3M Company beneficially owned 25,569,190 shares, or approximately 14.75%, of the outstanding shares of Solventum Corporation common stock.
    (b)Percent of class:

    The percent of class is based on 173,387,798 shares of common stock outstanding as July 31, 2025, as reported in Solventum Corporation's Quarterly Report on Form 10-Q for the period ended June 30, 2025, filed with the Securities and Exchange Commission on August 8, 2025. 14.75%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0. In connection with the separation of Solventum Corporation from 3M Company, 3M Company and Solventum Corporation entered into a Stockholder and Registration Rights Agreement, dated as of March 31, 2024, pursuant to which 3M Company granted to Solventum Corporation a proxy to vote the shares of Solventum Corporation common stock owned by 3M Company in proportion to the votes cast by Solventum Corporation's other stockholders. As a result, 3M Company does not exercise voting power over any of the shares of Solventum Corporation common stock that it beneficially owns.

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    25,569,190

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    3M Company
     
    Signature:3M Company
    Name/Title:Kevin H. Rhodes, Executive Vice President, Chief Legal Affairs Officer & Secretary
    Date:08/18/2025
    Get the next $SOLV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SOLV

    DatePrice TargetRatingAnalyst
    7/15/2025$103.00Equal-Weight → Overweight
    Morgan Stanley
    7/1/2025$90.00Hold → Buy
    Argus
    6/6/2025Sector Weight
    KeyBanc Capital Markets
    5/19/2025$87.00Neutral → Overweight
    Piper Sandler
    12/4/2024$70.00Neutral
    Mizuho
    10/8/2024$82.00Buy
    Stifel
    10/7/2024$71.00Neutral
    Piper Sandler
    9/26/2024Peer Perform
    Wolfe Research
    More analyst ratings

    $SOLV
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Solventum Corporation

    SCHEDULE 13G/A - Solventum Corp (0001964738) (Subject)

    8/18/25 5:03:26 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Solventum Corp (0001964738) (Filer)

    8/15/25 4:13:53 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    SEC Form 424B7 filed by Solventum Corporation

    424B7 - Solventum Corp (0001964738) (Filer)

    8/14/25 5:19:35 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Solventum Announces Pricing of Secondary Offering of Common Stock

    ST. PAUL, Minn., Aug. 13, 2025 /PRNewswire/ -- Solventum Corporation (NYSE:SOLV) (the "Company" or "Solventum") today announced the pricing of the previously announced secondary offering (the "Offering") of 8,800,000 shares of its common stock, which is expected to result in gross proceeds of approximately $648 million to 3M Company (the "Selling Shareholder"). All of the shares of common stock are being sold by the Selling Shareholder, and Solventum will not receive any of the proceeds from the Offering. The Offering is expected to close on or about Aug. 15, 2025, subject to customary closing conditions.

    8/13/25 10:39:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Announces Launch of Secondary Offering of Common Stock

    ST. PAUL, Minn., Aug. 13, 2025 /PRNewswire/ -- Solventum Corporation (NYSE:SOLV, ", Company", or ", Solventum", )) today announced the launch of a secondary offering (the "Offering") of 8,800,000 shares of its common stock, par value $0.01 per share, by 3M Company (the "Selling Shareholder"). All of the shares of common stock are being sold by the Selling Shareholder, and Solventum will not receive any proceeds from the Offering.  Goldman Sachs & Co. LLC and BofA Securities, Inc. will act as the underwriters for the Offering. The shares of common stock are being offered pursua

    8/13/25 4:48:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Reports Second Quarter 2025 Financial Results

    Reported sales increased 3.9%; organic sales increased 2.8%Increases full year organic sales growth outlook to +2.0% to +3.0%Increases full year earnings per share outlook to $5.80 to $5.95ST. PAUL, Minn., Aug. 7, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Sales increased 3.9% to $2.2 billion; up 2.8% on an organic basisGAAP diluted earnings per share of $0.51; adjusted diluted earnings per share of $1.69Operating cash flow of $169 million; free cash flow of $59 million"

    8/7/25 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $SOLV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Solventum upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Solventum from Equal-Weight to Overweight and set a new price target of $103.00

    7/15/25 8:30:16 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum upgraded by Argus with a new price target

    Argus upgraded Solventum from Hold to Buy and set a new price target of $90.00

    7/1/25 8:13:22 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    KeyBanc Capital Markets initiated coverage on Solventum Corporation

    KeyBanc Capital Markets initiated coverage of Solventum Corporation with a rating of Sector Weight

    6/6/25 8:37:20 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Large owner 3m Co sold $646,360,000 worth of shares (8,800,000 units at $73.45), decreasing direct ownership by 26% to 25,569,190 units (SEC Form 4)

    4 - Solventum Corp (0001964738) (Issuer)

    8/18/25 5:02:54 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Director Cox Carrie Smith converted options into 5,148 shares (SEC Form 4)

    4 - Solventum Corp (0001964738) (Issuer)

    5/15/25 4:23:40 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Hanson Bryan C converted options into 34,315 shares and covered exercise/tax liability with 13,503 shares, increasing direct ownership by 51% to 61,605 units (SEC Form 4)

    4 - Solventum Corp (0001964738) (Issuer)

    5/15/25 4:23:28 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Financials

    Live finance-specific insights

    View All

    Solventum Reports Second Quarter 2025 Financial Results

    Reported sales increased 3.9%; organic sales increased 2.8%Increases full year organic sales growth outlook to +2.0% to +3.0%Increases full year earnings per share outlook to $5.80 to $5.95ST. PAUL, Minn., Aug. 7, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Sales increased 3.9% to $2.2 billion; up 2.8% on an organic basisGAAP diluted earnings per share of $0.51; adjusted diluted earnings per share of $1.69Operating cash flow of $169 million; free cash flow of $59 million"

    8/7/25 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum to Report Second Quarter Fiscal 2025 Earnings on August 7, 2025

    ST. PAUL, Minn., July 17, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its second quarter fiscal 2025 financial results on Thursday, Aug. 7, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, Aug. 7, 2025 Time: 3:30 p.m. CDT / 4:30 p.m. EDT Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 International dial-in: +1 (

    7/17/25 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Reports First Quarter 2025 Financial Results

    Reported sales increased 2.6%; organic sales increased 4.3%Increases full year organic sales growth outlook by 50 bps to +1.5% to +2.5%ST. PAUL, Minn., May 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales increased 2.6% to $2.1 billion; up 4.3% on an organic basisGAAP diluted earnings per share of $0.78; adjusted diluted earnings per share of $1.34Operating cash flow of $29 million; free cash flow of $(80) million"Our first quarter fiscal year 2025 results reflect soli

    5/8/25 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Leadership Updates

    Live Leadership Updates

    View All

    Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors

    BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics. "We are thrilled to welcome Elizabeth to Ampersand's Board as we leverage our AND Platform to

    2/11/25 8:00:00 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing

    Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker BOSTON, Jan. 8, 2025 /PRNewswire/ -- The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Eliza

    1/8/25 6:30:00 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Names Surgeon and Diagnostics Pioneer Dr. Ryan Egeland as Chief Medical Officer

    ST. PAUL, Minn., Oct. 10, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that Dr. Ryan Egeland, MD, has been named chief medical officer. Dr. Egeland is responsible for leading Solventum's Global Medical and Clinical Affairs team, amplifying the voice of clinicians and patients. In this role, he will focus on fostering industry collaboration and identifying innovation and market expansion opportunities at the intersection of scientific rigor, clinical need, and commercial practicality. Dr. Egeland will report to Chris Barry, executive vice president and group presi

    10/10/24 9:00:00 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Solventum Corporation

    SC 13G/A - Solventum Corp (0001964738) (Subject)

    11/12/24 5:47:11 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Solventum Corporation

    SC 13G/A - Solventum Corp (0001964738) (Subject)

    11/4/24 1:47:43 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care